Can changes in dialysis treatment decrease substances which are related to ageing

Completed

• Conditions: Cardiovascular disease in hemodialysis patients; Circulatory System

• Registration Number: ISRCTN13837553
• Lead Sponsor: orrlands University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-16
• Last Update Posted: 6 February 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Adult patients (age > 18 years), no upper limit of age
2. Chronic dialysis treatment (patients with dialysis treatment more than three months)
3. All patients treated at the dialysis unit at Norrlands university hospital, Umeå, Sweden, who give informed consent and have no exclusion criterias

Exclusion Criteria

1. Ongoing infection (elevated CRP)
2. Inability to understand information and give informed consent
3. Patients with diabetes mellitus prone to hypoglycemia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Skin autofluorescence is measured using the AGE Reader (DiagnOptics Technologies BV, Groningen, The Netherlands) at baseline, 1 and 2 weeks after dialysate is switched to glucose free dialysate.

Secondary Outcome Measures

Name	Time	Method
Plasma autofluorescence is measured using a Tecan Genios microplate reader (Tecan Group Ltd., Männedorf, Switzerland) at baseline, 1 and 2 weeks after dialysate is switched to glucose free dialysate.